<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456663</url>
  </required_header>
  <id_info>
    <org_study_id>CAFQ056A2123</org_study_id>
    <secondary_id>2011-000748-28</secondary_id>
    <nct_id>NCT01456663</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects</brief_title>
  <official_title>A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetics of AFQ056 in subjects with mild, moderate, severe&#xD;
      hepatic impairment compared with healthy control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Profile of Pharmacokinetics of AFQ056 in each subjects groups</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 36, 48, 72, 96, 120 hours post-dose</time_frame>
    <description>AUClast, AUCinf, Cmax, Tmax, T1/2, CL/F, Vz/F</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure: : Number of subjects with adverse event in each group</measure>
    <time_frame>From dose administration (day 1) to 13+/- 2 days after the single dose administration</time_frame>
    <description>Number and type of adverse events, number and type of findings in standard laboratory results, special laboratory results (Hypothaliamic-pituitary axis, porphyrin profile) electrocardiogram holters, or in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Plasma protein binding results of AFQ056 in each groups.</measure>
    <time_frame>2 hours after single dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>AFQ056</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFQ056</intervention_name>
    <arm_group_label>AFQ056</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Groups 1, 2, 3 and 4 (all subjects)&#xD;
&#xD;
          -  Male and female Caucasian subjects&#xD;
&#xD;
          -  Group 1, 2 and 3 (subjects with hepatic impairment)&#xD;
&#xD;
          -  Subjects must satisfy the criteria for hepatic impairment as evidenced by a Child-Pugh&#xD;
             score of A, B or C at screening&#xD;
&#xD;
          -  Group 4 (healthy subjects)&#xD;
&#xD;
          -  Each healthy subject must match in age (±8 years), gender, weight (±15%) to an&#xD;
             individual subject with hepatic impairment in group 1, 2 or 3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Groups 1, 2, 3 and 4 (all subjects)&#xD;
&#xD;
          -  Use of any tobacco products from 1 week prior to cotinine screening assessments until&#xD;
             study completion.&#xD;
&#xD;
          -  Group 1, 2 and 3 (subjects with hepatic impairment)&#xD;
&#xD;
          -  History of drug or alcohol abuse within 3 months prior to screening&#xD;
&#xD;
          -  History or presence of any clinically significant disease of any major system organ&#xD;
             class including (but not limited to) cardiovascular, metabolic, renal, neurological or&#xD;
             psychiatric diseases within 1 month prior to study drug administration except for&#xD;
             hepatic impairment or any other disease associated with this underlying condition.&#xD;
&#xD;
          -  Any surgical or medical condition other than hepatic impairment which might&#xD;
             significantly alter the absorption, distribution, metabolism, or excretion of drugs,&#xD;
             or which may jeopardize the safety of the study subject in case of participation in&#xD;
             the study.&#xD;
&#xD;
          -  History or presence of encephalopathy within 6 months prior screening (except for&#xD;
             subjects in Groups 2 and 3).&#xD;
&#xD;
          -  Documented presence of a porto-systemic shunt.&#xD;
&#xD;
          -  Documented presence of esophagus varices (stage III or IV).&#xD;
&#xD;
          -  Group 4 (healthy subjects)&#xD;
&#xD;
          -  History or presence of any clinically significant disease of any major system organ&#xD;
             class including (but not limited to) cardiovascular, metabolic, renal, neurological or&#xD;
             psychiatric diseases.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of&#xD;
             the study subject in case of participation in the study. History of drug or alcohol&#xD;
             abuse within 12 months prior to screening, or evidence of such abuse as indicated by&#xD;
             the laboratory assays conducted during screening and baseline.&#xD;
&#xD;
          -  History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen&#xD;
             (HBsAg) or Hepatitis C test result at screening.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Lithuania</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9464</url>
    <description>Results for CAFQ056A2123 can be found on the Novartis Clinical Trial Results website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2011</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AFQ056</keyword>
  <keyword>Hepatic impairment</keyword>
  <keyword>Hepatic impaired</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

